Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid. Xiao Y, Gu Y, Xia D, Zhou X, et al. J Dermatol 2022 Aug 26. doi: 10.1111/1346-8138.16559.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xiao Y, Gu Y, Xia D, Zhou X, et al. Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid. J Dermatol 2022 Aug 26. doi: 10.1111/1346-8138.16559.
PMID: 36028948